| Schedule of Segment Reporting Information, by Segment |
The tables below present information about reported segments, unallocated corporate operations as well as geographic information for the three months ended March 31, 2026 and 2025:
|
|
|
|
|
|
|
|
|
|
|
For the three months ended March 31, |
|
(In thousands) |
|
2026 |
|
|
2025 |
|
Revenue from services: |
|
|
|
|
|
|
Pharmaceutical |
|
$ |
— |
|
|
$ |
— |
|
Diagnostics |
|
|
72,186 |
|
|
|
102,844 |
|
Corporate |
|
|
— |
|
|
|
— |
|
|
|
$ |
72,186 |
|
|
$ |
102,844 |
|
Revenue from products: |
|
|
|
|
|
|
Pharmaceutical |
|
$ |
38,042 |
|
|
$ |
34,842 |
|
Diagnostics |
|
|
— |
|
|
|
— |
|
Corporate |
|
|
— |
|
|
|
— |
|
|
|
$ |
38,042 |
|
|
$ |
34,842 |
|
Revenue from transfer of intellectual property and other: |
|
|
|
|
|
|
Pharmaceutical |
|
$ |
13,968 |
|
|
$ |
12,266 |
|
Diagnostics |
|
|
— |
|
|
|
— |
|
Corporate |
|
|
— |
|
|
|
— |
|
|
|
$ |
13,968 |
|
|
$ |
12,266 |
|
Cost of revenue: |
|
|
|
|
|
|
Pharmaceutical |
|
$ |
22,298 |
|
|
$ |
22,814 |
|
Diagnostics |
|
|
56,143 |
|
|
|
84,518 |
|
Corporate |
|
|
— |
|
|
|
— |
|
|
|
$ |
78,441 |
|
|
$ |
107,332 |
|
Gross margin: |
|
|
|
|
|
|
Pharmaceutical |
|
$ |
29,712 |
|
|
$ |
24,294 |
|
Diagnostics |
|
|
16,043 |
|
|
|
18,326 |
|
Corporate |
|
|
— |
|
|
|
— |
|
|
|
$ |
45,755 |
|
|
$ |
42,620 |
|
Selling, general and administrative: |
|
|
|
|
|
|
Pharmaceutical |
|
$ |
14,205 |
|
|
$ |
12,710 |
|
Diagnostics |
|
|
26,151 |
|
|
|
37,956 |
|
Corporate |
|
|
8,251 |
|
|
|
8,420 |
|
|
|
$ |
48,607 |
|
|
$ |
59,086 |
|
Research and development: |
|
|
|
|
|
|
Pharmaceutical |
|
$ |
28,753 |
|
|
$ |
30,238 |
|
Diagnostics |
|
|
312 |
|
|
|
538 |
|
Corporate |
|
|
134 |
|
|
|
65 |
|
|
|
$ |
29,199 |
|
|
$ |
30,841 |
|
Amortization of intangible assets: |
|
|
|
|
|
|
Pharmaceutical |
|
$ |
16,433 |
|
|
$ |
16,111 |
|
Diagnostics |
|
|
2,533 |
|
|
|
3,750 |
|
Corporate |
|
|
— |
|
|
|
— |
|
|
|
$ |
18,966 |
|
|
$ |
19,861 |
|
Segment operating loss: |
|
|
|
|
|
|
Pharmaceutical |
|
$ |
(29,679 |
) |
|
$ |
(34,765 |
) |
Diagnostics |
|
|
(12,953 |
) |
|
|
(23,918 |
) |
Corporate |
|
|
(8,385 |
) |
|
|
(8,485 |
) |
|
|
$ |
(51,017 |
) |
|
$ |
(67,168 |
) |
|
|
|
|
|
|
|
|
|
|
|
For the three months ended March 31, |
|
|
|
2026 |
|
|
2025 |
|
Depreciation and amortization: |
|
|
|
|
|
|
Pharmaceutical |
|
$ |
18,260 |
|
|
$ |
17,788 |
|
Diagnostics |
|
|
3,926 |
|
|
|
5,699 |
|
Corporate |
|
|
15 |
|
|
|
— |
|
|
|
$ |
22,201 |
|
|
$ |
23,487 |
|
Revenues: |
|
|
|
|
|
|
United States |
|
$ |
83,504 |
|
|
$ |
116,207 |
|
Ireland |
|
|
9,680 |
|
|
|
5,480 |
|
Chile |
|
|
14,869 |
|
|
|
14,532 |
|
Spain |
|
|
8,049 |
|
|
|
6,439 |
|
Israel |
|
|
(0 |
) |
|
|
73 |
|
Mexico |
|
|
6,940 |
|
|
|
6,229 |
|
Other |
|
|
1,154 |
|
|
|
992 |
|
|
|
$ |
124,196 |
|
|
$ |
149,952 |
|
|
| Reconciliation of Assets from Segment to Consolidated |
Segment assets for the two reportable segments in which we operate are shown in the following tables. Corporate assets are principally cash and are not allocated to an operating segment. Identifiable assets by segment are those assets that are used in our operations in each segment. The accounting policies of the segments are the same as those described in Note 3 summary of significant accounting policies.
|
|
|
|
|
|
|
|
|
March 31, |
|
|
December 31, |
|
(In thousands) |
2026 |
|
|
2025 |
|
Assets: |
|
|
|
|
|
Pharmaceutical |
$ |
1,302,316 |
|
|
$ |
1,326,400 |
|
Diagnostics |
|
343,371 |
|
|
|
349,095 |
|
Corporate |
|
211,109 |
|
|
|
256,449 |
|
|
$ |
1,856,796 |
|
|
$ |
1,931,944 |
|
Goodwill: |
|
|
|
|
|
Pharmaceutical |
$ |
318,826 |
|
|
$ |
320,847 |
|
Diagnostics |
|
163,442 |
|
|
|
163,442 |
|
|
$ |
482,268 |
|
|
$ |
484,289 |
|
|